Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
ENCERT: A Phase 1 Trial Using Everolimus in Combination With Nelarabine, Cyclophosphamide and Etoposide in Relapsed T Cell Lymphoblastic Leukemia/Lymphoma
Study Type: Treatment
Phase: I
NCTID: NCT03328104
Principal Investigator:
Kevin Ginn
A Phase I Study of Patient-Derived Multi-Tumor-Associated Antigen-Specific T-Cells MT-601 Administered to Patients with Relapsed or refractory Non-Hodgkin Lymphoma NHL [APOLLO]
Study Type: Treatment
Phase: I
NCTID: NCT05798897
Principal Investigator:
Haitham Abdelhakim
A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
Study Type: Treatment
Phase: III
NCTID: NCT03267433
Principal Investigator:
Nausheen Ahmed
An Open-label, Multicenter Phase 2 Study Evaluating the Efficacy and Safety of CRG-022, a CD22-Directed Autologous Chimeric Antigen Receptor CAR T-Cell Therapy in Patients With Relapsed/Refractory Large B-Cell Lymphoma FIRCE-1
A Randomized Phase II Trial of Consolidation Therapy Following CD19 CAR T-cell Treatment for Relapsed/Refractory Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma
Study Type: Treatment
Phase: II
NCTID: NCT05633615
Principal Investigator:
Marc Hoffmann
A Randomized Phase II Study of CDX-1127 Varlilumab in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-cell Lymphomas
A Phase Ib/II, Open-Label Study Of PF-07901801 In Combination with Glofitamab After a Fixed, Single Dose of Obinutuzumab in Participants with Relapsed/Refractory Diffuse Large B Cell Lymphoma Not Eligible for Stem Cell Transplantation
Study Type: Treatment
Phase: I/II
NCTID: NCT05896163
Principal Investigator:
Marc Hoffmann
A Phase Ib, Open Label, Global, Multicenter, Dose Determination, Randomized Dose Expansion Study To Determine The Maximum Tolerated Dose, Assess The Safety And Tolerability, Pharmacokinetics And Preliminary Efficacy Of Iberdomide CC-220 In Combination With R-CHOP21 And CC-99282 In Combination With R-CHOP21 For Subjects With Previously Untreated, Poor Risk IPI 3-5, Aggressive B-Cell Lymphoma
Study Type: Treatment
Phase: I
NCTID: NCT04884035
Principal Investigator:
Marc Hoffmann
A Randomized, Open-Label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants with Minimal Residual Disease After Response to First Line Therapy for Large B-Cell Lymphoma ALPHA3
Study Type: Treatment
Phase: II
NCTID: NCT06500273
Principal Investigator:
Rajat Bansal
A Multicenter, Open-label, Phase II Basket Study to Evaluate the Safety and Efficacy of MK-2140 as a Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell malignancies waveLINE-006
Study Type: Treatment
Phase: II
NCTID: NCT05458297
Principal Investigator:
Marc Hoffmann